Dendrimers in therapy for breast and colorectal cancer

Current Medicinal Chemistry

Volumn 19, Issue 29, 2012, Pages 4896-4902

  Stanczyk, M ^a   Dziki, A ^b   Morawiec, Z ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; Cancer; Colorectal cancer; Dendrimers; Nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; HYDROXYAPATITE; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METHOTREXATE; NANOCARRIER; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; POLYAMIDOAMINE; PROTEIN KINASE B; RIBOFLAVIN; SMALL INTERFERING RNA; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; CPG ISLAND; DIETARY INTAKE; DISEASE FREE SURVIVAL; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE THERAPY; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; MICROSATELLITE INSTABILITY; NANODEVICE; NANOTECHNOLOGY; OVERALL SURVIVAL; POINT MUTATION; SCHOOL; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; SURVIVAL RATE; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DENDRIMERS; DRUG CARRIERS; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES;

EID: 84870464259     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311209024896     Document Type: Article

References (51)

1. Zatoński, W.; Didkowska, J. Closing the gap: cancer in Central and Eastern Europe (CEE). Eur. J. Cancer., 2008 Jul, 44(10), 1425-37
2. Parkin, D.M.; Pisani, P.; Ferlay, J. Global Cancer statistics. CA. Cancer J. Clin., 1999,49(1),33
3. Wesolowski, R.; Ramaswamy, B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr., 2011,15(3),105-15
4. Tsang, R.Y.; Finn, R.S. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br. J. Cancer., 2012 Jan 3,106(1),6-13
5. Kothari, M.S.; Rusby, J.E.; Agusti, A.A.; MacNeill, F.A. Sentinel lymph node biopsy after previous axillary surgery: A review. Eur. J. Surg. Oncol., 2012 Jan,38(1),8-15
6. Moriya, T.; Kanomata, N.; Kozuka Y. Molecular morphological approach to the pathological study of development and advancement of human breast cancer. Med. Mol. Morphol ., 2010 Jun,43(2),67-73
7. Jemal, A.; Singer, R.; Ward, E. Cancer statistics 2007. CA. Cancer J. Clin., 2007,57(1),53
8. Philips, K.A.; Liang, K.Y. Trends for colonoscopy for colorectal cancer screening. Med. Care., 2007, 45,160
9. Watson, A.J.; Collins, P.D. Colon cancer: a civilization disorder. Dig Dis., 2011, 29(2), 222-8
10. Sweetser, S.; Smyrk, T.C.;, Sugumar, A. Serrated polyps: critical precursors to colorectal cancer. Expert Rev Gastroenterol. Hepatol., 2011 Oct,5(5),627-35
11. Nakatsumi, H.; Yuki, S.; Kobayashi, Y.; Komatsu, Y. Colorectal cancer chemotherapy and QOL (benefits and problems of outpatient-chemotherapy). Nihon Rinsho., 2011 Apr,69 Suppl 3,585-8
12. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov., 2005,4,145-160
13. Morotti, M.; Valenzano-Menada, M.; Venturini, P.L.; Ferrero.; S. Pharmacocinetics of pegylated liposomal Doxorubicin; review of animal and human studies. Clin. Pharmacokinet., 2003,42,419-36
14. Rakowski, J. A.; Ahmad, S.; Holloway, R. W. Use of pegylated liposomal doxorubicin in the management of platinium-sensitive recurent ovarian cancer; current concepts. Expert Rev. Anticancer Ther., 2012 Jan 12(1),31-40
15. Liu, Z.; Chen, K.; Davis, C.; Sherlock, S.; Cao, Q.; Chen, X. and Dai, H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res., 2008, 68, 6652-6660
16. Piccard, A.; Cheung, W.; Pontoriero, F.; Taratula, O.; Chen, A.M.; He, H. The next big nano thing. DNA and carbon nanotubes as medicine. Stanford Medicine Magazine., 2006, 23,3,3
17. Adv. Drug Deliv. Rev., 2010, 62, 633
18. Sawant, R.R.; Torchilin, V.P. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol. Membr. Biol., 2010 Oct,7(7),232-46
19. Boas, U.; Heegaard, P.M. Dendrimers in drug research. Chem. Soc. Rev., 2004, Jan, 10, 33(1),43-63
20. Kirkpatrick, G.J.; Plumb, J.A.; at all Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J. Inorg. Biochem., 2011, Sep;105(9),1115-22
21. Tansey,W.; Ke, S. Synthesis and characterization of branched poly(Lglutamic acid) as biodegradable drug carrier. J. Control. Release., 2004 Jan 8,94(1),39-51
22. Sajja, H.K.; East, M.P. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect., Curr Drug Discov Technol., 2009 Mar,6(1),43-51
23. Bosnjakovic, A.; Mishra, M.K.; Ren, W. Poly(amidoamine) dendrimererythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. Nanomedicine., 2011 Jun,7,3,284-94
24. Wu, G.; Barth, R.F.; Yang, W .; et all Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimerbioconjugates., Mol. Cancer Ther., 2006, Jan,5(1),52-9
25. Ward, B.B.; Dunham, T.; Majoros, I.J.; Baker, J.R.Jr. Targeted dendrimer chemotherapy in an animal model for head and necksquamous cell carcinoma. J. Oral Maxillofac. Surg., 2011, Sep,69(9),2452-9
26. Han, L.; Huang, R.; Liu, S.; Huang, S.; Jiang, C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol. Pharm., 2010, Dec 6,7(6),2156-65
27. Cao, W.; Zhou, J.; Mann, A.; Wang, Y.; Zhu, L.; Folate-functionalized unimolecular micelles based on a degradable amphiphilicdendrimer-like star polymer for cancer cell-targeted drug delivery. Biomacromolecules., 2011, Jul, 11,12(7),2697-707
28. Witte AB, Timmer CM, Gam JJet All;. Biophysical characterization of a riboflavin-conjugated dendrimer platform fortargeted drug delivery. Biomacromolecules. 2012 Feb 13;13(2):507-16
29. Miyano, T.; Wijagkanalan, W.;et all Anionic amino acid dendrimertrastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol. Pharm., 2010, Aug, 2,7(4),1318-27.
30. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A.K.; Thomas, T.; Mulé, J.; Baker, J.R. Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res., 2002, Sep,19(9),1310-6.
31. Alcala, M.A.; Shade, C.M.; Uh, H.; Kwan, S.Y at all; Preferential accumulation within tumors and in vivo imaging by functionalized luminescent dendrimer lanthanide complexes. Biomaterials., 2011, Dec,32(35),9343-52.
32. Kobayashi, H.; Ogawa, M.; Kosaka, N.; Choyke, P.L.; Urano, Y. Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond.)., 2009, Jun,4(4),411-9.
33. Coles, D. J.; Toth, I. Dendritic peptide-based carriers for gene delivery. Curr. Drug. Deliv., 2009, Aug,6(4),338-42.
34. Yuan, Q.; Yeudall, W.A.; Yang, H. PEGylatedpolyamidoaminedendrimers with bis-aryl hydrazone linkages for enhanced gene delivery. Biomacromolecules., 2010, Aug, 9,11(8),1940-7.
35. Pandita, D.; Santos, J.L.; Rodrigues, J.; Pêgo, A.P.; Granja, P.L.; Tomás, H. Gene delivery into mesenchymal stem cells: a biomimetic approach using RGD nanoclusters based on poly(amidoamine) dendrimers. Biomacromolecules., 2011, Feb, 14,12(2),472-81.
36. Patil, M.L.; Zhang, M.; Minko, T. Multifunctional triblockNanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS. Nano., 2011, Mar 22,5(3),1877-87.
37. Zhu, S.; Hong, M.; Zhang, L.; Tang,G.; Jiang, Y.; Pei, Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm. Res. 2010, Jan,27(1),161-74
38. Lee, I.H.; Yu, M.K.; Kim, I.H.; Lee, J.H.; Park, T.G.; Jon, S. A duplex oligodeoxynucleotide-dendrimerbioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy. J. Control. Release., 2011, Oct, 10,155(1),88-95
39. Lai, P.S.; Lou, P.J.; Peng, C.L.; Pai, C.L.; Yen, W.N.; Huang, M.Y.; Young, T.H.; Shieh, M.J. Doxorubicin delivery by polyamidoaminedendrimer conjugation and photochemical internalization for cancer therapy. J Control Release., 2007, Sep 11,122(1),39-46.
40. Khandare, J.J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T.; Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug. Chem., 2006, Nov-Dec,17(6),1464-72.
41. Clementi, C.; Miller, K.; Mero, A.; Satchi-Fainaro, R.; Pasut, G. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm., 2011, Aug, 1,8(4),1063-72
42. Lo, S.T.; Stern, S.; Clogston, J.D.; at all Biological assessment of triazinedendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol. Pharm., 2010, Aug 2,7(4),993-1006
43. Yellepeddi, V.K.; Kumar, A.; Maher, D.M.; Chauhan, S.C.; Vangara, K.K.; Palakurthi, S. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res., 2011, Mar,31(3),897-906.
44. Miyano, T.; Wijagkanalan, W.; Kawakami, S.; Yamashita, F.; Hashida, M. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol Pharm. 2010 Aug 2;7(4):1318-27.
45. Güç, E.; Gündüz, G.; Gündüz, U. Fatty acid based hyperbranched polymeric nanoparticles for hydrophobic drug delivery. Drug. DevInd. Pharm., 2010, Oct,36(10),1139-48.
46. Jin, Y.; Ren, X.; Wang, W.; Ke, L.; Ning, E.; Du, L.; Bradshaw, J. A 5- fluorouracil-loaded pH-responsive dendrimernanocarrier for tumor targeting. Int. J. Pharm., 2011, Nov, 28,420(2),378-84.
47. Morgan, M.T.; Nakanishi, Y.; Kroll, D.J.; at all. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res., 2006, Dec, 15,66(24),11913-21.
48. Vijayalakshmi, N.; Ray, A.; Malugin, A.; Ghandehari, H. Carboxylterminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation. Bioconjug. Chem. 2010, Oct, 2021(10),1804-10
49. Goldberg, D.S.; Vijayalakshmi, N.; Swaan, P.W.; Ghandehari, H.; G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J. Control Release., 2011, Mar 30,150(3),318-25
50. Peng, C.; Zheng, L.; Chen, Q.; Shen, M.; Guo, R.; Wang, H.; Cao, X.; Zhang, G.; Shi, X. PEGylateddendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography. Biomaterials., 2012 Feb,33(4),1107-19.
51. Fernandez-Fernandez, A,; Manchanda, R.; McGoron, A.J. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl. Biochem. Biotechnol., 2011 Dec,165(7-8),1628-51.